TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00646906
Drug: Acetaminophen 1000 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
Study: NCT00646906
Drug: Ibuprofen 800 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
Study: NCT00401739
Drug: CSL360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV Infusion. Dose escalation study.
Study: NCT02931136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will treatment by the placebo in 52 weeks.
Study: NCT03302195
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Based on patient body weight (UI/kg)
Study: NCT02840240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
Study: NCT01348607
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02126358
Drug: Gemigliptin and/or Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01240876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo vials will be filled with the buffered solution for CEP-37247.
Study: NCT03141073
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID oral administration
Study: NCT03141073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID oral administration
Study: NCT01737450
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03090412
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo PDT
Study: NCT04603937
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT04104334
Drug: Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
Study: NCT04104334
Drug: Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
Study: NCT03115073
Drug: Candiplus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Candiplus
Study: NCT04541888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00928252
Drug: IV fluorine-18 labeled methylcholine before PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention at pre-treatment, and at two timepoints post treatment intiation.
Study: NCT01385631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
Study: NCT00057954
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)
Study: NCT00315146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00808678
Drug: ABT-143
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: once, see arm description for more information
Study: NCT00808678
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: once, see arm description for more information
Study: NCT00808678
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once, see arm description for more detail
Study: NCT03630211
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stem Cell Mobilization
Study: NCT03098836
Drug: ARN-509
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg orally daily
Study: NCT00082589
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03887533
Drug: VTS-270
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
Study: NCT00002665
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
Study: NCT00530400
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative intravenous placebo
Study: NCT00002665
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: main: 25 mg/m2 IV 1, 8, 15, and 22
Study: NCT00002665
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
Study: NCT00002665
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: con: 60 mg/m2 PO 1 - 28
Study: NCT00002665
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
Study: NCT01993212
Drug: Androxal 12.5 mg or 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01993212
Drug: AndroGel 1.62%
Normalized name: Androgel 1.62% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01993212
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01993212
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT00864890
Drug: CelexaTM 40 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Forest Labs formulated products under fed conditions
Study: NCT02753881
Drug: whole liver lobe cTACE doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin CTACE administered in a whole liver lobe manner.
Study: NCT03343067
Drug: estradiol/norethindrone acetate (E2/NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01669928
Drug: Anti-hypertensive Medication -
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).
Study: NCT03387683
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match dapagliflozin
Study: NCT01368432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill placebo
Study: NCT02753881
Drug: superselective cTACE doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
Study: NCT02738632
Drug: Telmisartan/Amlodipine+Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD
Study: NCT02738632
Drug: Placebo for Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01008150
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01008150
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02905656
Drug: Pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy in the form of gum.
Study: NCT01916967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, given orally, once daily in the evening for 2 weeks
Study: NCT04375618
Drug: Plain Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A collagen membrane without FGF-2 will be used.
Study: NCT00846287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will inhale a placebo (nebulized saline) with no drug.
Study: NCT03175354
Drug: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
Study: NCT03175354
Drug: ALX-101 Gel 5% and ALX-101 Gel Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
Study: NCT01271114
Drug: Normal saline and norepinephrine
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
Study: NCT02044835
Drug: Fu-zheng-qu-zhuo oral liquid
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
Study: NCT00986856
Drug: Fucidin® cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02787551
Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Study: NCT00753779
Drug: colesevelam HCl tablets, and simvastatin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
Study: NCT00753779
Drug: simvastatin tablets and colesevelam HCl placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
Study: NCT04383002
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iNO will be given at 160ppm for 6 hours, once a day, for 2 days
Study: NCT02361190
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
Study: NCT02361190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 1ml aqueous saline spray
Study: NCT02218359
Drug: Amikacin Fosfomycin Inhalation Solution
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
Study: NCT01878617
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Route of Administration (ROA): Intravenously (IV)
Study: NCT02218359
Drug: Aerosolized placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
Study: NCT02218359
Drug: Amikacin Fosfomycin Inhalation Solution
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label crossover for all patients Days 6-10
Study: NCT01677559
Drug: MLN8237
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04807127
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI, administered as standard-of-care treatment
Study: NCT00002582
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002582
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002582
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002582
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002582
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04556773
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: administered orally
Study: NCT01541553
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Field treatment with vehicle gel once daily for 3 consecutive days.
Study: NCT01218620
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02634281
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study: NCT03048461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injections to an area of alopecia
Study: NCT02693392
Drug: Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents
Study: NCT01872689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
Study: NCT00424801
Drug: Amiloride, hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
Study: NCT05115578
Drug: Remifentanil 1 MG Injection [Ultiva]
Normalized name: remifentanil 1 MG Injection [Ultiva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
Study: NCT02939079
Drug: Placebo (for Fish Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules to mimic Fish Oil 1 g capsules
Study: NCT01697358
Drug: Optimal Medical Management (OMM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
Study: NCT02874287
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
Study: NCT00276874
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; 0 mg; oral; daily
Study: NCT00915356
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Study: NCT00915356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Study: NCT04150939
Drug: Immunotherapeutic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard of care immunotherapy
Study: NCT03298373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
Study: NCT03298373
Drug: 11β-methyl-nortestosterone-dodecylcarbonate
Normalized name: 17-Ethynyl-18-methyl-19-nortestosterone
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
Study: NCT02558387
Drug: BIBF1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
Study: NCT02463071
Drug: AZD0585
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g soft capsule
Study: NCT02463071
Drug: AZD0585 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g soft capsule
Study: NCT00600535
Drug: Stage 3: glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
Study: NCT00600535
Drug: Stage 4: glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
Study: NCT03773367
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Study: NCT02035501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04489459
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
Study: NCT00623025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 to 9 capsules placebo per day
Study: NCT01634763
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02297191
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01470794
Drug: Toca FC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01346969
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administered by injection four different times
Study: NCT01346969
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
Study: NCT01346969
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
Study: NCT01346969
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
Study: NCT01978535
Drug: Iron infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
Study: NCT01658852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00053092
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01175356
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01175356
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02867124
Drug: XR-NTX
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivitrol
Study: NCT01433731
Drug: placebo for SHAPE (SHP-141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gelled solution
Study: NCT01433731
Drug: SHAPE (SHP-141) 0.1% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gelled solution
Study: NCT01433731
Drug: SHAPE (SHP-141) 0.5% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gelled solution
Study: NCT01433731
Drug: SHAPE (SHP-141) 1.0% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gelled solution
Study: NCT02674776
Drug: HuZhen Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take 4 tablet once and 3 times per day for 3 days.
Study: NCT02674776
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take 4 tablet once and 3 times per day for 3 days.
Study: NCT01687140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
Study: NCT03103581
Drug: BLI4700
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI4700 Bowel Preparation (Investigational Regimen)
Study: NCT01937598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients administered a single dose of placebo during a mixed meal challenge.
Study: NCT04345770
Drug: SOX neoadjuvant or postoperative chemotherapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.